Creative Medical Technology Holdings, Inc.

NasdaqCM CELZ

Creative Medical Technology Holdings, Inc. Price to Sales Ratio (P/S) on January 14, 2025: 341.62

Creative Medical Technology Holdings, Inc. Price to Sales Ratio (P/S) is 341.62 on January 14, 2025, a -59.38% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Creative Medical Technology Holdings, Inc. 52-week high Price to Sales Ratio (P/S) is 1,249.94 on March 11, 2024, which is 265.88% above the current Price to Sales Ratio (P/S).
Creative Medical Technology Holdings, Inc. 52-week low Price to Sales Ratio (P/S) is 303.00 on August 09, 2024, which is -11.30% below the current Price to Sales Ratio (P/S).
Creative Medical Technology Holdings, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 635.69.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqCM: CELZ

Creative Medical Technology Holdings, Inc.

CEO	Mr. Timothy Warbington
IPO Date	Nov. 6, 2015
Location	United States
Headquarters	211 East Osborn Road
Employees	4
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine to treat chronic lower back pain; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

Key trends

Past 5 years